Giulio Metro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4779179/publications.pdf

Version: 2024-02-01

202	3,942	117625	175258
papers	citations	34 h-index	52 g-index

206	206	206	5727
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology and Oncology, 2022, 15, 9.	17.0	5
2	Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and Therapy, 2022, 10, 291-300.	2.6	1
3	Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2022, 14, 816-819.	1.4	2
4	Host immuneâ€inflammatory markers to unravel the heterogeneous outcome and assessment of patients with <scp>PDâ€L1</scp> â‰¥50% metastatic nonâ€small cell lung cancer and poor performance status receiving firstâ€line immunotherapy. Thoracic Cancer, 2022, 13, 483-488.	1.9	7
5	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. Cancers, 2022, 14, 3337.	3.7	21
6	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clinical Lung Cancer, 2021, 22, e180-e192.	2.6	15
7	Afatinib in EGFR TKI-naÃ¯ve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer, 2021, 152, 127-134.	2.0	17
8	Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 965-980.	2.8	12
9	Smoking status during firstâ€line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A caseâ€“control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	1.9	30
10	High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. Genes, 2021, 12, 273.	2.4	14
11	Supportive Care: Low Cost, High Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 240-250.	3.8	6
12	Upfront pembrolizumab as an effective treatment start in patients with PD-L1â€‰â‰¥â€‰50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis. Clinical and Translational Oncology, 2021, 23, 1818-1826.	2.4	11
13	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
14	Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. Cancer Immunology, Immunotherapy, 2021, 70, 3041-3053.	4.2	19
15	The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 â‰¥ 50% advanced non-small-cell lung cancer. ESMO Open, 2021, 6, 100078.	4.5	35
16	Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Genes, 2021, 12, 679.	2.4	25
17	Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma. Human Vaccines and Immunotherapeutics, 2021, 17, 2972-2980.	3.3	5
18	Post-progression outcomes of NSCLC patients with PD-L1 expression â‰¥ 50% receiving first-line single-agent pembrolizumab in a large multicentreÂreal-world study. European Journal of Cancer, 2021, 148, 24-35.	2.8	19

#	Article	IF	Citations
19	Predictive ability of a drug-based score in patients with advanced nonâ€“small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	2.8	24
20	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes, 2021, 12, 992.	2.4	5
21	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 3713-3736.	2.8	12
22	PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm. Translational Lung Cancer Research, 2021, 10, 4617-4630.	2.8	2
23	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Clinical and Translational Oncology, 2020, 22, 708-716.	2.4	6
24	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Nonâ€“Small Cell Lung Cancer With a PD-L1 Expression â‰¥50%. Journal of Immunotherapy, 2020, 43, 299-306.	2.4	18
25	Baseline neutrophil-to-lymphocyte ratio and PD-L1 expression level or LDH value may predict outcome of patients with high PD-L1 advanced non-small cell lung cancer treated with first-line pembrolizumab. Lung Cancer, 2020, 139, S58-S59.	2.0	0
26	Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review. Oncology and Therapy, 2020, 8, 341-350.	2.6	3
27	Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Translational Lung Cancer Research, 2020, 9, 1533-1542.	2.8	43
28	New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma. Acta Neuropathologica Communications, 2020, 8, 145.	5.2	13
29	Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients. Frontiers in Oncology, 2020, 10, 1299.	2.8	20
30	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. Annals of Oncology, 2020, 31, S825-S826.	1.2	2
31	Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR. Diagnostics, 2020, 10, 1062.	2.6	10
32	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of â‰¥â€‰50%. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	4.2	60
33	RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature. Oncology and Therapy, 2020, 8, 333-339.	2.6	16
34	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score â‰¥50% treated with front-line pembrolizumab. Acta OncolÃ³gica, 2020, 59, 1058-1063.	1.8	31
35	Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool. Frontiers in Immunology, 2020, 11, 839.	4.8	28
36	The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. Clinical Lung Cancer, 2020, 21, e539-e543.	2.6	19

#	Article	IF	Citations
37	Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. Journal of Clinical Medicine, 2020, 9, 1047.	2.4	47
38	Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Nonâ€“small-cell Lung Cancer Progressing on Crizotinib. Clinical Lung Cancer, 2020, 21, e478-e487.	2.6	2
39	Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1>50%.. Journal of Clinical Oncology, 2020, 38, e21651-e21651.	1.6	4
40	ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. Future Oncology, 2019, 15, 3003-3014.	2.4	42
41	Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 2019, 134, 210-217.	2.0	12
42	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). Tumori, 2019, 105, 3-14.	1.1	9
43	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. Journal of Neuro-Oncology, 2019, 144, 211-216.	2.9	3
44	Afatinib in EGFR TKI-naÃ¯ve patients with EGFR mutation-positive (EGFRm+) NSCLC: Interim analysis of a phase IIIb, multi-national, open-label study. Annals of Oncology, 2019, 30, v598-v599.	1.2	0
45	Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest. Annals of Oncology, 2019, 30, v622-v623.	1.2	0
46	Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS). Annals of Oncology, 2019, 30, v624.	1.2	2
47	Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma. Molecular Therapy - Nucleic Acids, 2019, 16, 543-553.	5.1	52
48	Chemotherapy with immune-checkpoint inhibitors in first-line treatment metastatic NSCLC patients: Systematic review and literature-based meta-analysis. Annals of Oncology, 2019, 30, ii57.	1.2	0
49	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. Frontiers in Oncology, 2019, 9, 264.	2.8	87
50	Afatinib in EGFR TKI-naÃ¯ve patients (pts) with locally advanced/metastatic NSCLC harbouring EGFR mutations: An interim analysis of a phase IIIB trial. Annals of Oncology, 2019, 30, ii48-ii49.	1.2	1
51	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
52	Safety and Efficacy of Nivolumab in Patients With Advanced Nonâ€“small-cell Lung Cancer Treated Beyond Progression. Clinical Lung Cancer, 2019, 20, 178-185.e2.	2.6	35
53	Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?. Lung Cancer Management, 2019, 8, LMT18.	1.5	17
54	Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naÃ¯ve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option. Translational Lung Cancer Research, 2019, 8, S378-S382.	2.8	1

#	Article	IF	Citations
55	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Translational Lung Cancer Research, 2019, 8, 1163-1173.	2.8	34
56	P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-NaÃ¯ve Patients with EGFRm+ NSCLC: An Interim Analysis. Journal of Thoracic Oncology, 2019, 14, S853-S854.	1.1	0
57	P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S742-S743.	1.1	0
58	Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naÃ¯ve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC. Annals of Oncology, 2019, 30, ix161-ix162.	1.2	1
59	P1.16-09 Post-Progression Outcomes After Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort. Journal of Thoracic Oncology, 2019, 14, S589.	1.1	1
60	P1.01-65 Immune Gene Expression, Bayesian Network and Genetic Mutation Analysis in Advanced NSCLC Patients Treated with Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S384-S385.	1.1	0
61	Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 159-168.	2.8	27
62	Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Journal of Cancer Research and Clinical Oncology, 2019, 145, 479-485.	2.5	253
63	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 â‰¥50% who progress on first-line immunotherapy: real-world data from a European cohort. Journal of Thoracic Disease, 2019, 11, 4972-4981.	1.4	35
64	Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: A systematic review and literature-based meta-analysis.. Journal of Clinical Oncology, 2019, 37, e20565-e20565.	1.6	0
65	Immune gene expression and bayesian network analysis in advanced non small cell lung cancer (NSCLC) patients treated with immunotherapy.. Journal of Clinical Oncology, 2019, 37, e20693-e20693.	1.6	1
66	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Future Oncology, 2018, 14, 353-361.	2.4	3
67	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Medical Oncology, 2018, 35, 72.	2.5	29
68	Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung Cancer, 2018, 120, 70-74.	2.0	5
69	Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. Journal of Thoracic Oncology, 2018, 13, e9-e12.	1.1	8
70	Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. International Journal of Biological Markers, 2018, 33, 549-550.	1.8	0
71	CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles. CardioVascular and Interventional Radiology, 2018, 41, 284-290.	2.0	14
72	Fatal acute disseminated intravascular coagulation as presentation of advanced ALK -positive non-small cell lung cancer: Does oncogene addiction matter?. Thrombosis Research, 2018, 163, 51-53.	1.7	12

#	Article	IF	Citations
73	EGFR targeted therapy for lung cancer: are we almost there?. Translational Lung Cancer Research, 2018, 7, S142-S145.	2.8	7
74	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. Translational Lung Cancer Research, 2018, 7, S294-S296.	2.8	2
75	Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?. Journal of Thoracic Disease, 2018, 10, S3890-S3894.	1.4	9
76	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. Translational Lung Cancer Research, 2018, 7, S290-S293.	2.8	2
77	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M-positive non-small cell lung cancer (NSCLC) - European subset. Annals of Oncology, 2018, 29, viii528.	1.2	0
78	MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M-Positive NSCLC. Journal of Thoracic Oncology, 2018, 13, S358-S359.	1.1	1
79	MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S390-S391.	1.1	4
80	P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience. Journal of Thoracic Oncology, 2018, 13, S490-S491.	1.1	0
81	KRAS mutation and DNA repair and synthesis genes in nonâ€'smallâ€'cell lung cancer. Molecular and Clinical Oncology, 2018, 9, 689-696.	1.0	7
82	Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e220-e222.	1.1	5
83	Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. Clinical Drug Investigation, 2018, 38, 983-987.	2.2	14
84	27P ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. Journal of Thoracic Oncology, 2018, 13, S14-S15.	1.1	0
85	Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. Journal of Thoracic Oncology, 2018, 13, e145-e147.	1.1	15
86	Osimertinib. Recent Results in Cancer Research, 2018, 211, 257-276.	1.8	24
87	Immune-related adverse events to predict survival in patients with advanced non-small cell lung cancer treated with nivolumab: A multicenter analysis.. Journal of Clinical Oncology, 2018, 36, 9084-9084.	1.6	2
88	First-line alectinib for ALK-positive lung cancer: is there room for further improvement?. Drugs in Context, 2018, 7, 1-6.	2.2	3
89	P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice. Journal of Thoracic Oncology, 2017, 12, S706-S707.	1.1	0
90	Optimal management of ALK -positive NSCLC progressing on crizotinib. Lung Cancer, 2017, 106, 58-66.	2.0	33

#	Article	IF	Citations
91	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Medical Oncology, 2017, 34, 105.	2.5	47
92	Long-Lasting Response toÂNivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Nonâ€“Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e51-e55.	1.1	3
93	The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 101-109.	2.4	8
94	Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 387-404.	3.2	30
95	P3.02b-008 Quantification and Monitoring of Treatment Response in EGFR Mutant NSCLC Patients by Digital-PCR in Plasma cftDNA. Journal of Thoracic Oncology, 2017, 12, S1189-S1190.	1.1	0
96	P3.02c-068 Immunotherapy against Non-Small Cell Lung Cancer (NSCLC): Looking for Predictive Factors to Avoid an Untargeted Shooting. Journal of Thoracic Oncology, 2017, 12, S1317-S1318.	1.1	0
97	MA04.06 Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair. Journal of Thoracic Oncology, 2017, 12, S360-S361.	1.1	0
98	Large Cell Neuroendocrine Carcinoma Transformation and EGFR -T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clinic Proceedings, 2017, 92, 1304-1311.	3.0	24
99	Therapeutic approach to brain metastasis in high-grade neuroendocrine carcinomas of the lung: where do we stand?. Journal of Radiation Oncology, 2017, 6, 11-19.	0.7	1
100	ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort. Annals of Oncology, 2017, 28, vi54.	1.2	0
101	Efficacy of platinum-based chemotherapy in EGFR WT nonsquamous advanced non-small cell lung cancer (NSCLC) patients: association with KRAS mutation and thymidylate synthase (TS) levels. Annals of Oncology, 2017, 28, vi58-vi59.	1.2	0
102	Efficacy of ceritinib in a "real-world" population of crizotinib-refractory ALK-positive NSCLCs: Results of the Italian compassionate use program. Annals of Oncology, 2017, 28, ii38.	1.2	0
103	Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program. Annals of Oncology, 2017, 28, vi56-vi57.	1.2	0
104	Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinomaâ€. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 856-861.	1.1	13
105	Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Gastroenterology Research and Practice, 2017, 2017, 1-9.	1.5	9
106	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori, 2017, 103, 405-421.	1.1	52
107	Targeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort. Annals of Oncology, 2017, 28, ii9.	1.2	1
108	Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy. Journal of Thoracic Disease, 2017, 9, 4064-4069.	1.4	7

#	Article	IF	Citations
109	ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9036-9036.	1.6	10
110	Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. Journal of Breast Cancer, 2016, 19, 324.	1.9	14
111	Malignant Giant Solitary Fibrous Tumor of the Pleura Metastatic to the Thyroid Gland. Tumori, 2016, 102, S16-S21.	1.1	6
112	Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 2016, 95, 82-87.	2.0	19
113	Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-NaÃ¯ve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Clinical Drug Investigation, 2016, 36, 683-686.	2.2	27
114	How might treatment of ALK-positive non-small cell lung cancer change in the near future?. Expert Review of Anticancer Therapy, 2016, 16, 997-999.	2.4	2
115	Alectinibâ€™s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. Journal of Neuro-Oncology, 2016, 129, 355-361.	2.9	25
116	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Management, 2016, 5, 79-90.	1.5	1
117	Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Medical Oncology, 2016, 33, 18.	2.5	129
118	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine, 2016, 10, 53-68.	2.5	56
119	Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis. Oncotarget, 2016, 7, 30561-30574.	1.8	37
120	Programmed cell death ligand 1(PD-L1), Programmed death 1+(PD-1) lymphocytes and Tumor infiltrating lymphocytes (TILs): are they playing a role in predicting response to anti-PD-1 therapies?. Journal of Clinical Oncology, 2016, 34, e20652-e20652.	1.6	0
121	Quantification and monitoring of treatment response in EGFR mutant non-small cell lung cancer patients using Digital PCR and Therascreen in plasma cell-free tumour DNA.. Journal of Clinical Oncology, 2016, 34, e23037-e23037.	1.6	0
122	Preface on â€œEmerging treatment options for brain metastases from non-small cell lung cancerâ€. Translational Lung Cancer Research, 2016, 5, 561-562.	2.8	1
123	Sacrum colon-rectal cancer metastasis: microwave ablation for palliative pain treatment. Recenti Progressi in Medicina, 2016, 107, 673-676.	0.8	1
124	CSF Concentration of Crizotinib in Two ALK-Positive Nonâ€“Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment. Journal of Thoracic Oncology, 2015, 10, e26-e27.	1.1	93
125	Sequential strategy with ALK-TKIs for ALK-positive advanced NSCLC: results of a multicenter analysis. Annals of Oncology, 2015, 26, vi75.	1.2	1
126	Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis. Annals of Oncology, 2015, 26, vi78.	1.2	3

#	Article	IF	Citations
127	Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. Ecancermedicalscience, 2015, 9, 559.	1.1	11
128	miRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: beyond â€˜traditional mechanismsâ€™ of resistance. Ecancermedicalscience, 2015, 9, 569.	1.1	12
129	Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. Clinical Lung Cancer, 2015, 16, e223-e228.	2.6	44
130	Future options for ALK-positive non-small cell lung cancer. Lung Cancer, 2015, 87, 211-219.	2.0	50
131	Letter to the editor concerning â€˜Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIAâ€™. Annals of Oncology, 2015, 26, 1033-1034.	1.2	2
132	Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Cancer Treatment Reviews, 2015, 41, 401-411.	7.7	40
133	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2015, 16, 2601-2613.	1.8	22
134	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. Lung Cancer, 2015, 90, 255-260.	2.0	43
135	Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas. BioMed Research International, 2014, 2014, 1-7.	1.9	12
136	Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. European Respiratory Review, 2014, 23, 79-91.	7.1	51
137	Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Nonâ€"Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. Clinical Lung Cancer, 2014, 15, 86-92.	2.6	40
138	Dramatic Response to Crizotinib in ROS1 Fluorescent In Situ Hybridization- and Immunohistochemistry-Positive Lung Adenocarcinoma: A Case Series. Clinical Lung Cancer, 2014, 15, 470-474.	2.6	13
139	Correlation of circulating miRNA levels with progression-free survival (PFS) and overall survival (OS) in early-stage lung adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 11099-11099.	1.6	1
140	Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. Journal of Clinical Oncology, 2014, 32, 7600-7600.	1.6	1
141	Non-coding RNAs in lung cancer. Oncoscience, 2014, 1, 674-705.	2.2	33
142	Do â€œpan-negativeâ€•never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience.. Journal of Clinical Oncology, 2014, 32, e19054-e19054.	1.6	0
143	Clinical features and outcome in never-smoker (NS) non-small cell lung cancer (NSCLC) patients (pts): A single-institution observational analysis.. Journal of Clinical Oncology, 2014, 32, e22152-e22152.	1.6	0
144	Targeting angiogenesis in advanced non-small-cell lung cancer: are biomarkers needed?. Current Respiratory Care Reports, 2013, 2, 72-78.	0.6	0

#	Article	IF	Citations
145	Selumetinib: a promising pharmacologic approach forKRAS-mutant advanced non-small-cell lung cancer. Future Oncology, 2013, 9, 167-177.	2.4	19
146	Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Annals of Oncology, 2012, 23, 1436-1441.	1.2	31
147	Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer, 2012, 12, 482.	2.6	20
148	Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer, 2012, 78, 81-86.	2.0	68
149	Efficacy of the Irreversible EGFR-HER2 Dual Inhibitor Afatinib in Pretreated Lung Adenocarcinoma. Annals of Oncology, 2012, 23, ix423.	1.2	0
150	Clinical Impact of Presence and Type of Kras Mutation in a Population of EGFR Wild Type (WT) Advanced Non-Small Cell Lung Cancer (NSCLC) Patients (PTS) Treated with Platinum-Based Chemotherapy: A Retrospective Analysis. Annals of Oncology, 2012, 23, ix427.	1.2	1
151	Emerging drugs for small cell lung cancer â€“ an update. Expert Opinion on Emerging Drugs, 2012, 17, 31-36.	2.4	20
152	New Target Therapies for Brain Metastases from Breast Cancer. Current Cancer Drug Targets, 2012, 12, 210-217.	1.6	6
153	Targeted Therapies for Non-small-Cell Lung Cancer. , 2012, , 93-114.		0
154	Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?. Journal of Thoracic Disease, 2012, 4, 635-8.	1.4	3
155	Advances on EGFR mutation for lung cancer. Translational Lung Cancer Research, 2012, 1, 5-13.	2.8	46
156	HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. Clinical Cancer Research, 2011, 17, 2055-2064.	7.0	92
157	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 673-682.	2.4	44
158	Phase Iâ€“II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. Cancer Chemotherapy and Pharmacology, 2011, 67, 687-693.	2.3	8
159	Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemotherapy and Pharmacology, 2011, 68, 1405-1412.	2.3	19
160	Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. Journal of Experimental and Clinical Cancer Research, 2011, 30, 10.	8.6	89
161	Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile?. Journal of Clinical Oncology, 2011, 29, 2834-2835.	1.6	5
162	Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Annals of Oncology, 2011, 22, 625-630.	1.2	146

#	Article	IF	Citations
163	Glioblastoma Patients: Role of Methylated MGMT. , 2011, , 73-79.		0
164	Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients.. Journal of Clinical Oncology, 2011, 29, e11027-e11027.	1.6	0
165	Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy.. Journal of Clinical Oncology, 2011, 29, 568-568.	1.6	0
166	Clinical outcome of KRAS-mutated advanced non-small cell lung cancer (NSCLC) patients (pts): A mono-institutional analysis.. Journal of Clinical Oncology, 2011, 29, 7580-7580.	1.6	0
167	Supportive care in neurooncology. Current Opinion in Oncology, 2010, 22, 621-626.	2.4	45
168	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemotherapy and Pharmacology, 2010, 65, 391-397.	2.3	27
169	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. Journal of Neuro-Oncology, 2010, 100, 209-215.	2.9	17
170	Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab-Based Therapy beyond Progression in HER-2 Positive Metastatic Breast Cancer. Breast Journal, 2010, 16, 66-72.	1.0	8
171	Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies. Oncology, 2010, 78, 141-149.	1.9	29
172	Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC).. Journal of Clinical Oncology, 2010, 28, 1155-1155.	1.6	1
173	Individualized administration of capecitabine plus lapatinib in heavily pretreated HER2+ metastatic breast cancer patients: A single-center experience.. Journal of Clinical Oncology, 2010, 28, 1108-1108.	1.6	0
174	Correlation of efficacy between EGFR gene copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2010, 28, 1059-1059.	1.6	1
175	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. BMC Cancer, 2009, 9, 101.	2.6	28
176	Emerging drugs for small-cell lung cancer. Expert Opinion on Emerging Drugs, 2009, 14, 591-606.	2.4	20
177	In SituProtein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy. Cancer Investigation, 2009, 28, 172-180.	1.3	23
178	New targeted therapies for non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 335-350.	0.2	4
179	EGFR Gene Copy Number and Response to Lapatinib/Capecitabine in HER2 Positive Metastatic Breast Cancer Patients Pretreated with Trastuzumab.. , 2009, , .		0
180	Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Research, 2009, 29, 2607-10.	1.1	26

#	Article	IF	Citations
181	Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. Journal of Neuro-Oncology, 2008, 87, 79-84.	2.9	13
182	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemotherapy and Pharmacology, 2008, 62, 717-725.	2.3	39
183	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. Supportive Care in Cancer, 2008, 16, 1375-1380.	2.2	11
184	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast, 2008, 17, 499-505.	2.2	47
185	HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opinion on Pharmacotherapy, 2008, 9, 2583-2601.	1.8	43
186	COX-2 targeting in cancer: a new beginning?. Annals of Oncology, 2008, 19, 1209-1210.	1.2	3
187	Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer. Journal of Clinical Oncology, 2008, 26, 1071-1071.	1.6	1
188	Changes in HER2 overexpression between primary tumor and autologous metastases: Correlations with clinical and biological features. Journal of Clinical Oncology, 2008, 26, 11071-11071.	1.6	2
189	Trastuzumab-related cardiotoxicity in setting outside clinical trials: A mono-institutional experience. Journal of Clinical Oncology, 2008, 26, 22116-22116.	1.6	0
190	Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. Anticancer Research, 2008, 28, 1245-58.	1.1	9
191	Aromatase inhibitors in post-menopausal metastatic breast carcinoma. Expert Opinion on Investigational Drugs, 2007, 16, 1023-1036.	4.1	4
192	Clinical Utility of Continuing Trastuzumab Beyond Brain Progression in HERâ€2â€“Positive Metastatic Breast Cancer. Oncologist, 2007, 12, 1467-1469.	3.7	34
193	2509 POSTER Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): preliminary results. European Journal of Cancer, Supplement, 2007, 5, 230.	2.2	0
194	Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC). Journal of Clinical Oncology, 2007, 25, 1066-1066.	1.6	3
195	Fixed dose rate (FDR) gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM): Preliminary results of a phase II study. Journal of Clinical Oncology, 2007, 25, 12502-12502.	1.6	0
196	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13.	0.8	44
197	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	4.4	50
198	Development of gemcitabine in non-small cell lung cancer: the Italian contribution. Annals of Oncology, 2006, 17, v37-v46.	1.2	11

#	Article	IF	Citations
199	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Annals of Oncology, 2006, 17, ii42-ii45.	1.2	28
200	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	1.2	93
201	Treatment of advanced non-small cell lung cancer. Annals of Oncology, 2006, 17, ii36-ii41.	1.2	31
202	Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. Frontiers in Oncology, 0, 12, .	2.8	5